Prosecution Insights
Last updated: November 04, 2026
Application No. 18/667,926

Viral vector packaging cells made from cell hybrids

Final Rejection §103§112
Filed
May 17, 2024
Priority
Jun 09, 2022 — provisional 63/350,863 +1 more
Examiner
WANG, RUIXUE
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cho Plus Inc.
OA Round
4 (Final)
56%
Grant Probability
Moderate
5-6
OA Rounds
10m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
68 granted / 122 resolved
-4.3% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
55 currently pending
Career history
185
Total Applications
across all art units

Statute-Specific Performance

§101
5.0%
-35.0% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
36.5%
-3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 122 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Acknowledgement is hereby made of receipt and entry of the communication filed on July 27, 2025. Claims 1, 3-18 and 20 are pending. Claims 5, 8, 12, 14-15 and 17-18 are withdrawn. Claims 1, 3, 4, 6, 7, 9, 10, 11, 13, 16, and 20 are currently examined. Claim Rejections - 35 USC § 112 (Written Description) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. (Previous rejection- withdrawn) Claims 1, 3-4, 6-7, 9-11, 13, 16 and 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is withdrawn in view of the amendment filed on July 27, 2025. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. (New Rejection-necessitated by amendment) Claims 1, 6-7, 9-10, 13 and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Kondo et al. (2004 Nov;35(5):1120-6) as evidenced by Li et al. (Electron J Biotechnol. 2019 Sep; 41:56-59) and in view of Liu et al. (US 8,703,480 B1, Patented on Apr. 22, 2014). The base claims 1 and 20 are directed to a viral vector or viral particle packaging cell line, wherein each cell is progeny of a hybrid cell that constitutes a fusion of two or more parental cells from a starting mammalian cell line; wherein the starting cell line is characterized as being capable of producing a AAV or LV vector or particle when transfected to express viral genes that encode the viral vector or particle; wherein the packaging cell line already contains said viral genes, and produces at least 2-fold more of the viral vector or particle per volume of culture fluid than does the starting cell line when transfected to express the same viral genes, where the claim 20 further requires that the starting cell line are transfected to express said viral genes and a transgene encoding a payload, the packaging cell line produces at least 2-fold more of the viral vector or particle that encapsulates the payload than does the starting cell line. PNG media_image1.png 504 489 media_image1.png Greyscale Kondo et al. describes a study on detection of osteoclastic cell–cell fusion through retroviral vector packaging, and teaches two model systems demonstrating that cell–cell fusion results in retrovirus production when one cell contains defective retroviral vector and the other produces proteins for retroviral packaging (See page 1124, right column, paragraph 2). In one model system, Kondo et al. discloses using CHO cells as the starting cell line (See Fig. 1, page 1122 and below), and the vectors are the retroviral vectors, pBabe puro and pFB neo (Stratagene), which express inserted genes from the MLV long terminal terminal repeat (LTR) (See page 1121, left column, paragraph 4). CHO cell lines are transfected with the retroviral vectors and cell–cell fusion is triggered by interaction between Env expressed on CHOpac cells and the receptor mCAT-1 on CHOmcat cells. CHOpac cells produced Env as well as Gag and Pol, and a specialized vector cell, CHOmcat, carried a retroviral vector expressing mCAT-1-GFP. Fusion between CHOpac and CHOmcat was detected by a novel cell fusion assay and fusion of these two cell types results in release of infectious retroviral particles into culture supernatant (See Fig. 1 above; page 1121, right column, paragraph 2; page 1124, right column, paragraph 3). Accordingly, Kondo et al. teaches a viral vector or viral particle packaging cell line, where each fused cell is from CHO cells containing viral genes, and the cell–cell fusion can result in the production of infectious retroviruses carrying a fusion-inducing gene. Here the CHO cell is a widely used cell line for producing large quantities of recombinant proteins, including particles like viral vectors or virus-like particles, which teaches the limitations in the instant claims. As an example of evidence of CHO cells used as a packaging cell line, Li et al. teaches retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines (See Title). Li et al. teaches a CHO cell transfection using a transfer plasmid (pRDM-GLP-1-Fc or pLEGFPC1) and packaging plasmids pMD2.G and pCMV-gag-pol, and then CHO cell transduction and stable cell line generation (See page 57, left column, paragraphs 3 & 4; right column, paragraphs 1 & 2). Li et al. teaches that suspension CHO cells are relatively safe, clean, and reliable packaging cells for retrovectors. Generation of CHO stable cells with these retrovectors eliminates virus contamination from serum and traditional packaging cells such as HEK-293 (See page 59, left column, paragraph 4; right column, paragraph 1). As for the limitation of “produces at least 2-fold more of the viral vector or particle per volume of culture fluid than does the starting cell line”, Kondo et al. does not specifically teach the 2-fold more viral vector or particle, however, Kondo et al. expressed GAL4-VP16 in CHOpac and the luciferase reporter in CHOmcat cells. As shown in Fig. 3, luciferase activity was significantly elevated 24 h after co-culturing CHOmcat and CHOpac cells comparing the transfection to the parent CHO cells, suggesting that fusion had occurred between these two types of cells (See page 1122, right column, paragraph 1; Fig. 3, page 1123 and below), which indicates 2-fold more of the viral vector or particle is produced comparing to the starting cell line CHO at 24 hours. PNG media_image2.png 567 645 media_image2.png Greyscale Based on the description above, Kondo et al. teaches the hybrid CHO cell lines producing higher retroviral particles of MLV. However, Kondo does not explicitly point out the virus can be a AAV or lentivirus. Liu et al. teaches a Hybrid Packaging Cells providing for efficient propagation of virus vectors, where the hybrid cells are derived from two cells (See column 26, lines 40-64) such as NIH 3T3, U937, H9 or 293 (See claim 8, column 56) and contains the genetic information for the production of the gag, pol and env sequences necessary for production of a virus particle as well as sequences for a selectable marker (See column 27, lines25-35). The viral vector or particle produced in the hybrid cells are AAV Vector Viruses from a heterologous vector retrovirus inactivated for ppt function and containing non-native vector components derived from AAV (See Example 8, column 40). Liu et al. further teaches that the heterologous vector retrovirus, incorporating into the retrovirus nucleic acid component of two such ITR sequences, can provide independent capabilities for the efficient propagation of said vector viruses in packaging cells and for the efficient gene delivery to target cells. Affinity for the packaging cell provides for propagation to high yields by the ability of propagated vector viruses to re-infect packaging cells and undergo repeated cycles of propagation (See column 17, lines 40-50; Column 18, lines 22-48). It would have been prima facie obvious for one having ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings from Kondo and Liu to develop a hybrid cell line expressing heterologous vector (retrovirus vector) DNA construct containing two AAV ITR sequences that flank the primer binding site (See Fig. 10, Liu et al.). One of skill in the art would have been motivated to do so based on the advantage as described above, and there would have been a reasonable expectation of success to arrive at an invention as claimed in the instant application. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was made. Regarding claims 6-7, they require packaging cell line also contain a transgene where the packaging cell line produces a greater percentage of viral vectors or particles containing that contain said payload compared to the start cells. Kondo et al. teaches the fused CHO cell line express the MLV retroviral vector inserted with a payload gene of Gal4-VP16 and luciferase (See page 1121, right column, paragraph 2; Fig. 3 above), and the luciferase expression shows more than 2-fold increasing at 24 h in the fusion cell lines (See Fig. 3, above and page 1122, right column, paragraph 1). Regarding claim 9, it requires that the payload includes a nucleic acid that encodes enhanced green fluorescent protein (eGFP) or another protein that emits a detectable signal. Kondo et al. teaches that the vector CHOmcat carried a retroviral vector expressing mCAT-1-GFP. Regarding claims 10 and 13, they require that the payload is a pharmaceutical agent and the nucleic acid for gene therapy of a subject in need. Kondo et al. teaches the lentiviral vector containing the payload gene but the gene is not specific for therapy. However, Li et al. teaches that the CHO packaging cell line expresses glucagon-like peptide-1 Fc fragment fusion protein (GLP-1-Fc), a long-acting GLP-1 analog for type 2 diabetes. The yield of GLP-1-Fc recombinant protein can reach 3.15 g/L. GLP-1-Fc produced from this method has comparable bioactivity to that of commercial GLP-1-Fc (dulaglutide) (See page 57, left column, paragraph 2). It would be obvious for one of ordinary skill in the art to add GLP-Fc into Kondo’s cell-cell fusion CHO cell system to express the GLP-Fc if a therapy of a type 2 diabetes patient is needed. One of skill in the art would have been motivated to do so if a high yield of GLP-1-Fc is needed for treating diabetes patient. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated and commonly used as evidenced by the prior art teachings. (New Rejection-necessitated by amendment) Claims 3, 4 and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Kondo et al. (2004 Nov;35(5):1120-6) as evidenced by Li et al. (Electron J Biotechnol. 2019 Sep; 41:56-59) and in view of Liu et al. (US 8,703,480 B1, Patented on Apr. 22, 2014).as applied to claims 1, 6-7, 9-10, 13 and 20 above, and in view of Landgrebe et al. (BMC Proc. 2011 Nov 22;5 Suppl 8(Suppl 8):P83) and Chakrabarti et al. (MAbs. 2022 Jan-Dec;14(1):2020081). Claims 3-4 require that cells of the packaging cell line contain substantially more mitochondria and/or more reactive oxygen species (ROS) per cell than cells from the starting cell line and cells from the packaging cell line have a level of staining that is at least 1.5-fold higher than cells from the starting cell line. Based on the description above, Kondo et al. teaches the fused CHO cell lines produce higher protein (See Fig. 3 above and page 1123), and does not explicitly point out selecting cells based on the staining of mitochondria and/or more reactive oxygen species (ROS) in cells. However, Kondo et al. teaches the same active steps of fusing CHO cells to produce the hybrid cells as claimed, thus the fused CHO cells of Kondo will have the same properties of claims 3, 4 and 16 (i.e., more mitochondria and/or more reactive oxygen species (ROS) than the starting cells has as claimed, where including the using of a dye to stain cells to show the higher-level staining in the fusion cells than the starting cells). (New Rejection-necessitated by amendment) Claims 11 is rejected under 35 U.S.C. 103 as being unpatentable over Kondo et al. (2004 Nov;35(5):1120-6) as evidenced by Li et al. (Electron J Biotechnol. 2019 Sep; 41:56-59) and in view of Liu et al. (US 8,703,480 B1, Patented on Apr. 22, 2014). as applied to claims 1, 6-7, 9-10, 13 and 20 above, and in view of Vasireddy et al. (PLoS One. 2015 Jun 19;10(6): e0129982). Claim 11 requires the expression of the nucleic acid payload in a human subject in vivo upon administration to a subject in need. Based on the description above, Kondo and Li teach the fused CHO cell lines produce higher protein such as GFP and GPL-1 Fc. However, it is silent on an administration to a human subject. Vasireddy et al. describes the AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. Vasireddy et al. teaches that Choroideremia (CHM) is an X- linked retinal degeneration that is symptomatic in the 1st or 2nd decade of life causing nyctalopia and loss of peripheral vision. CHM is a favorable target for gene augmentation therapy, as the disease is due to loss of function of a protein necessary for retinal cell health, Rab Escort Protein 1 (REP1).The CHM cDNA can be packaged in recombinant adeno-associated virus (rAAV), which has an established track record in human gene therapy studies. Delivery of the CHM cDNA to affected cells restores REP1 enzymatic activity and also restores proper protein trafficking. The gene transfer is efficient and the preliminary safety data are encouraging. These studies pave the way for a human clinical trial of gene therapy for CHM (See Abstract). Vasireddy et al. teaches the method for Generation of a Recombinant Adeno-associated Virus (AAV) Carrying the Full-length Human REP-1-encoding cDNA and transfecting the AAV vector into CHO cell line using Lipofectamine 2000 and Fugene-6 transfection reagent (See page 2, right column). Vasireddy et al. also teaches the Safety of Infection with AAV2.hCHM in vitro and in vivo by administrating AAV2. hCHM to wild type (C57Bl/6) mice, where the results of subretinal delivery of AAV2. hCHM show that transfer of the REP-1-encoding gene to retinal cells results in high levels of expression without significant evidence of toxicity. Vasireddy et al. discloses that the pAAV2.CBAe.hCHM construct will also be used to generate a clinical vector to be used in human clinical trials (See Competing Interests), which indicates a administration in human based on the needs as claimed. It would have been prima facie obvious for one having ordinary skill in the art before the effective filing date of the claimed invention to apply the AAV-based therapy into Kondo’s system to arrive at an invention as claimed. One of skill in the art would have been motivated to do so to express the AAV2. hCHM in Kondo’s system to test a possible better system for producing AAV2. hCHM in order to treat Choroideremia or other human disease. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated and commonly used as evidenced by the prior art teachings. Responses to Applicant’s Remarks Applicant’s arguments filed on July 27, 2026 have been received and fully considered. Applicant’s amendment and argument on the rejection under 35 USC § 112 (a) is considered. The rejection is withdrawn. Applicant’s argument on the rejection under 35 USC § 103 regarding Kondo’s Fig. 3 is not found persuasive (See Remarks, pages 7-8). 1). In Fig. 3, luciferase activity was significantly elevated 24 h after co-culturing CHOmcat and CHOpac cells, suggesting that fusion had occurred between these two types of cells (See Kondo et al., page 1122, right column, paragraph 1). Therefore, the level of the luciferase activity as a reporter gene represents the level of the production from the hybrid cells, which also indicates the viral particles are produced. In addition, the instant specification discloses that “Functional titer can be measured by cell transduction using a fluorescent or chemiluminescent protein as a reporter” (See Instant specification, e.g., [0136]), which discloses a comparable measurement method as the teachings did form Kondo. 2). Kondo teaches that a luciferase gene driven by a GAL4-dependent promoter was introduced into CHOpac and a chimeric GAL4-VP16 transcription factor was introduced into CHOmcat. Fusion of these two types of cells provided the reporter gene with the transcription activator and was measured as luciferase activity (See bridging pages 1124-1125), which indicates that the expression of luciferase is a marker of the cell hybrid. There will be no luciferase expression without fusion. 3). The instant base claim 1 does not recite a limitation or a specific mechanism for how to detect the cell fusion and monitor the increased reporter gene production. 4). On the other hand, the instant base claim 1 only requires fusing two starting cells that are capable of producing AAV or LV. Kondo teaches fusing two cells that already have viral genes in them (See Kondo, Fig. 1 below). Without further structural limitations in the claim, the fused cells of Kondo will produce viral particles at 2-fold as claimed. PNG media_image3.png 615 597 media_image3.png Greyscale 5). Applicant’s argument of “the luciferase assay confirmed that CHOmcat cells and CHOpac cells were being fused by the mCAT-1 gene, but it says nothing about vims production” is not persuasive (See Remarks, page 8). Kondo teaches that plasmids expressing virion proteins Gag, Pol, and Env were introduced into a separate culture of CHO cells to generate packaging cells. Co-culturing vector and packaging cells resulted in production of infectious retroviruses carrying the mCAT-1 gene as a consequence of cell–cell fusion (See Abstract), and they tested significant numbers of G418-resistant and GFP-positive Rat-1A cell colonies were observed when the co-culture supernatants of CHOmcat and CHOpac were titrated (175 F 35 cfu/ml). Such colonies were not observed with supernatants of CHO, CHOgfp, CHOmcat, or CHOpac cells alone, or co-cultures of all combinations of the two cell populations other than CHOmcat and CHOpac. These data show that cell–cell fusion can result in the production of infectious retroviruses carrying a fusion-inducing gene (See page 1122, right column, paragraph 1). Here it is also a response to the argument on the GFP activity in the Remarks (See Remarks, page 9, paragraph 1) and the arguments at “…but it says nothing about virus production” and “…there is no evidence in Kondo that hybridizing cells can increase the level of virus production…” in the Remarks (See Remarks, page 9). 3. Applicant argued the references of Li et al., Landgrebe et al., Chakrabarti et al., Vasireddy et al. and Liu et al. (See Remarks, page 9). The argument is not persuasive. Li is used here as evidence to show that CHO cells can be used as a packaging cell line. Landgrebe, Chakrabarti, Vasireddy and Liu are used here to teach specific limitation in the related claims. It is applicable to combine them with Kondo in the office action. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUIXUE WANG whose telephone number is (571)272-7960. The examiner can normally be reached Monday-Friday 8:00 am-5:00 pm, EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas J. Visone can be reached on (571) 270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUIXUE WANG/ Examiner, Art Unit 1672 /NICOLE KINSEY WHITE/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Show 6 earlier events
Jun 17, 2025
Applicant Interview (Telephonic)
Jun 25, 2025
Examiner Interview Summary
Jul 21, 2025
Request for Continued Examination
Jul 22, 2025
Response after Non-Final Action
Aug 22, 2025
Non-Final Rejection mailed — §103, §112
Mar 31, 2026
Response after Non-Final Action
Jul 27, 2026
Response Filed
Aug 06, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758601
ONCOLYTIC ADENOVIRUS WITH REPLICATION SELECTIVITY BASED ON STATUS OF P53 TRANSCRIPTIONAL ACTIVITY
3y 9m to grant Granted Oct 13, 2026
Patent 12735754
MULTIPLEX NUCLEIC ACID DETECTION SYSTEM
4y 8m to grant Granted Sep 15, 2026
Patent 12685765
POLYPEPTIDES MIMICKING MPER AND V3-LOOP HIV-1 ENV GLYCOPROTEIN EPITOPES
2y 11m to grant Granted Jul 21, 2026
Patent 12668783
Preparation method and application of vesicle formed by erythrocyte membrane encapsulating Newcastle disease virus
3y 4m to grant Granted Jun 30, 2026
Patent 12662512
CHIMERIC POLYPEPTIDES AND USES THEREOF
4y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
56%
Grant Probability
76%
With Interview (+20.1%)
3y 4m (~10m remaining)
Median Time to Grant
High
PTA Risk
Based on 122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month